Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
Poster available until
  • Monday 29 June 2026 (10)
  • Until platform closure (15)
Poster categories
  • Thematic Poster Session (27)
keywords
Session Reference
  • L-TPS01 (12)
  • L-TPS02 (14)
  • L-TPS03 (10)
  • L-TPS04 (13)
  • L-TPS05 (10)
  • L-TPS06 (8)
  • L-TPS07 (14)
  • L-TPS08 (9)
  • L-TPS09 (13)
  • L-TPS10 (14)
  • L-TPS11 (15)
  • L-TPS12 (11)
  • L-TPS13 (12)
  • L-TPS14 (14)
  • L-TPS15 (12)
  • L-TPS16 (9)
  • L-TPS17 (13)
  • L-TPS18 (13)
  • L-TPS19 (9)
  • L-TPS20 (14)
  • L-TPS21 (8)
  • L-TPS22 (10)
  • L-TPS23 (14)
  • L-TPS24 (14)
  • L-TPS25 (5)
  • TPS01 (14)
  • TPS02 (12)
  • TPS03 (10)
  • TPS04 (12)
  • TPS05 (13)
  • TPS06 (14)
  • TPS07 (9)
  • TPS08 (15)
  • TPS09 (14)
  • TPS10 (11)
  • TPS11 (13)
  • TPS12 (12)
  • TPS13 (11)
  • TPS14 (12)
  • TPS15 (9)
  • TPS16 (12)
  • TPS17 (12)
  • TPS18 (11)
  • x TPS19 (11)
  • TPS20 (13)
  • TPS21 (14)
  • TPS22 (11)
  • TPS23 (11)
  • TPS24 (12)
  • TPS25 (8)
  • TPS26 (16)
  • TPS27 (13)
  • TPS28 (5)
  • TPS29 (6)
  • TPS30 (12)
  • TPS31 (10)
  • TPS32 (12)
  • TPS33 (14)
  • TPS34 (15)
  • TPS35 (11)
  • TPS36 (11)
  • TPS37 (12)
  • TPS38 (12)
  • TPS39 (13)
  • TPS40 (10)
  • x TPS41 (14)
  • TPS42 (15)
  • TPS43 (15)
  • TPS44 (14)
  • TPS45 (12)
  • TPS46 (11)
  • TPS47 (14)
  • TPS48 (11)
  • TPS49 (12)
  • TPS50 (9)
  • TPS51 (8)
  • TPS52 (14)
  • TPS53 (12)
  • TPS54 (11)
  • x TPS55 (13)
  • TPS56 (13)
  • TPS57 (5)
  • TPS58 (4)
  • TPS59 (12)
  • TPS60 (12)
  • TPS61 (12)
  • TPS62 (13)
  • TPS63 (12)
  • TPS64 (15)
  • TPS65 (14)
  • TPS66 (13)
  • TPS67 (13)
  • TPS68 (11)
  • TPS69 (15)
  • TPS70 (13)
  • TPS71 (9)
  • TPS72 (13)
  • TPS73 (12)
  • TPS74 (10)
  • TPS75 (13)
  • TPS76 (10)
  • TPS77 (7)
  • TPS78 (14)
  • TPS79 (13)
  • TPS80 (11)
  • TPS81 (6)
  • TPS82 (12)
  • TPS83 (6)
  • TPS84 (11)
  • TPS85 (11)
  • TPS86 (13)
  • TPS87 (10)
  • TPS88 (9)
  • TPS89 (7)
  • TPS90 (5)
  • TPS91 (5)
38 results
Thumbnail

- D1.340 - Attack burden and patient-reported outcomes in adults with hereditary angioedema: associations with quality of life, pain, and coping strategies

Thumbnail

- D1.336 - Barriers to Normalization with Existing Treatments Among People Living with Hereditary Angioedema in Europe

Thumbnail

- D1.337 - Long-Term Safety, Tolerability, and Effectiveness of Berotralstat in Hereditary Angioedema: Interim Analysis of the APeX-N Post-Authorization Study

Thumbnail

- D1.338 - Divergent Clinical and Functional Consequences of Canonical NF-κB Pathway Defects

Thumbnail

- D1.339 - Renal and urinary tract disorders in inborn errors of immunity

Thumbnail

- D1.341 - Severe Atopic Features with Prematurity and Ichthyosis: Ichthyosis Prematurity Syndrome

Thumbnail

- D1.342 - Case Report: Off-Label Dosage of Berotralstat in Hereditary Angioedema

Thumbnail

- D1.343 - Common Variable Immunodeficiency Associated Enteropathy: A Single-Center Experience

Thumbnail

- D1.344 - Hidden Immunodeficiency in Adult Bronchiectasis: Lymphocyte Subsets, Humoral Defects, and Genetic Findings

Thumbnail

- D1.346 - Clinically significant gastrointestinal endoscopic findings in asymptomatic patients with common variable immunodeficiency

Thumbnail

- D1.347 - Lanadelumab in Children with Hereditary Angioedema Aged 2 to

Thumbnail

D2.216 - Effectiveness and safety of subcutaneous immunotherapy with Depigmented-Polymerized Cat Extract: real-world clinical evidence

Thumbnail

D2.217 - Structured Follow-Up Intervals Enhance Adherence to Sublingual Immunotherapy in Patients with Allergic Rhinitis: Real-World Evidence from a Stepwise Approach

Thumbnail

D2.218 - Effectiveness of the 300IR house dust mite sublingual tablet according to the patients’ sensitisation and allergy profile in the real-world, non-interventional VORAN study

Thumbnail

D2.219 - Effectiveness of the 300IR house dust mite sublingual tablet in the real-world, non-interventional VORAN study: a responder analysis

Thumbnail

D2.222 - A real-world observational study following the first year of SQ grass or SQ tree SLIT-tablet treatment to evaluate persistence and adherence in routine clinical practice among general practitioners in Norway

Thumbnail

D2.225 - Characterizing skin-resident antigen presenting cell responses to plant-based Fel d 1 Bioparticles

Thumbnail

D2.226 - Evaluation of the Immunogenicity and Stability of an Aluminum-Adsorbed Allergen Immunotherapy Using Specific IgG Titration in a Murine Model

Thumbnail

D2.228 - Effectiveness and Safety of Subcutaneous Immunotherapy for Patients Allergic to Either Cat Dander or Dermatophagoides/Cat Dander: Real World Data

Thumbnail

D2.214 - TAPAS – non-inferiority of clinical effectiveness in children compared to adults: 3-year interim results of a long-term NIS

Pagination

  • Current page 1
  • Page 2
  • Next page Next
  • Last page Last
Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2026 EAACI
Made with   by CYIM